Vaccines against human papillomavirus infections: protection against cancer, genital warts or both? (original) (raw)
HPV vaccines to prevent cervical cancer and genital warts: an update
Rita Verhelst
Vaccine, 2014
View PDFchevron_right
Human papilloma virus vaccination: Review article and an update
Zahra Maleki
View PDFchevron_right
Human papillomavirus, vaccines, and protection from cervical cancer
tapisiz tapisiz
Saudi Medical Journal, 2012
View PDFchevron_right
Human Papillomavirus Vaccine Efficacy and Effectiveness against Cancer
supitcha kamolratanakul
Vaccines
View PDFchevron_right
Human papillomavirus and HPV vaccines: a review
Xavier Castellsagué
Bulletin of the World Health Organization, 2007
View PDFchevron_right
Randomized Controlled Trial of an Adjuvanted Human Papillomavirus (HPV) Type 6 L2E7 Vaccine: Infection of External Anogenital Warts with Multiple HPV Types and Failure of Therapeutic Vaccination
Pierre Vandepapelière
The Journal of Infectious Diseases, 2005
View PDFchevron_right
The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus‐Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Sexually Active Women Aged 16–26 Years
Darron Brown
The Journal of Infectious Diseases, 2009
View PDFchevron_right
Clinical Trials of Human Papillomavirus Vaccines
Jorma Paavonen
Elsevier eBooks, 2020
View PDFchevron_right
Evaluating the impact of human papillomavirus vaccines
Jennifer S. Smith
2009
View PDFchevron_right
Human papillomavirus (including vaccination)
Alison Fiander
Obstetrics, Gynaecology & Reproductive Medicine, 2010
View PDFchevron_right
Human papillomavirus (including vaccines)
Alison Fiander
Obstetrics, Gynaecology & Reproductive Medicine, 2007
View PDFchevron_right
Vaccines against human papillomavirus: perspectives for controlling cervical cancer
Silvia C Galvan
Expert Review of Vaccines, 2007
View PDFchevron_right
The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus‐Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV‐Naive Women Aged 16–26 Years
Nubia Munoz
The Journal of Infectious Diseases, 2009
View PDFchevron_right
Human Papillomavirus Vaccination: Expected Impacts and Unresolved Issues
Gary Freed
The Journal of Pediatrics, 2008
View PDFchevron_right
Cross-protection from human papillomavirus 16/18 against types 45 and 31: fact or fancy?
Leo Twiggs
Therapy, 2008
View PDFchevron_right
Human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for the prevention of cervical cancer and HPV-related diseases
Rachel Skinner
Expert review of vaccines, 2016
View PDFchevron_right
Human Papillomavirus Vaccine:Its Application and Perspective
Kazuhiro Takehara
View PDFchevron_right
Abstracts from current global literature: Human papillomavirus vaccine
Dimpal Patel
Indian Journal of Sexually Transmitted Diseases and AIDS, 2015
View PDFchevron_right
“Human Papilloma Virus Vaccination for cervical cancer prevention. Is it safe and effective?”
Dr.Damitha Gunawardane
Bangladesh Journal of Medical Science, 2018
View PDFchevron_right
Monitoring Effect of Human Papillomavirus Vaccines in US Population, Emerging Infections Program, 2008–2012
Martin Steinau
Emerging Infectious Diseases, 2015
View PDFchevron_right
Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18
Robert Ronaldo
Vaccine, 2006
View PDFchevron_right
Epidemiology, clinical manifestations, and recent advances in vaccination against human papillomavirus
Robert Jacobson
Postgraduate Medicine, 2010
View PDFchevron_right
Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine
Helen Oh
Human Vaccines, 2011
View PDFchevron_right
The Past, Today, and the Future of Human Papilloma Virus Vaccines
Neziha Yilmaz
International Journal of Hematology and Oncology, 2011
View PDFchevron_right